As drug development grows more complex, organizations are simultaneously advancing next-generation therapies while adopting smarter, data-driven manufacturing approaches. Success depends on balancing innovative modalities such as viral vectors with the operational excellence needed to accelerate development, improve quality, and support scalable production.
From optimizing viral vector design and manufacturing processes for gene therapies to establishing the data governance, standardization, and monitoring frameworks that power AI-enabled decision-making, developers must overcome both scientific and operational challenges. Integrating advanced technologies across development and manufacturing can enhance efficiency, strengthen regulatory readiness, and improve overall program outcomes.
Discover how leading organizations are applying innovative approaches to viral vector development and AI-driven manufacturing in this edition of the Outsourced Pharma Capabilities Update (OPCU). Watch the presentations below to gain practical insights that can help accelerate and optimize your next program.
Recent Sessions Available On-Demand
Nanoparticles & Solid Dose Formulation – September 2026
Cell Line Development – August 2026
Large Molecule & Fill/Finish – August 2026
Gene Therapy – August 2026
Upcoming OPCU Topics & Times
Driving Biologics Manufacturing Innovation | 10/27/2026, AM Session
Fill/Finish Excellence | 10/27/2026, PM Session
Advancing Drug Substance Manufacturing | 10/28/2026, AM Session
Small Molecule Drug Product Innovation | 10/28/2026, AM Session
Enabling Success In Cell & Gene Therapy | 10/29/2026, AM Session
Advancing Analytical Capabilities | 10/29/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
